



RESEARCH

Open Access

# Fibroblast growth factor receptor 3 effects on proliferation and telomerase activity in sheep growth plate chondrocytes

Logan B Smith, Janelle M Belanger and Anita M Oberbauer\*

## Abstract

**Background:** Fibroblast growth factor receptor 3 (FGFR3) inhibits growth-plate chondrocyte proliferation and limits bone elongation. Gain-of-function FGFR3 mutations cause dwarfism, reduced telomerase activity and shorter telomeres in growth plate chondrocytes suggesting that FGFR3 reduces proliferative capacity, inhibits telomerase, and enhances senescence. Thyroid hormone ( $T_3$ ) plays a role in cellular maturation of growth plate chondrocytes and a known target of  $T_3$  is FGFR3. The present study addressed whether reduced FGFR3 expression enhanced telomerase activity, mRNA expression of telomerase reverse transcriptase (TERT) and RNA component of telomerase (TR), and chondrocyte proliferation, and whether the stimulation of FGFR3 by  $T_3$  evoked the opposite response.

**Results:** Sheep growth-plate proliferative zone chondrocytes were cultured and transfected with siRNA to reduce FGFR3 expression; FGFR3 siRNA reduced chondrocyte FGFR3 mRNA and protein resulting in greater proliferation and increased TERT mRNA expression and telomerase activity ( $p < 0.05$ ). Chondrocytes treated with  $T_3$  significantly enhanced FGFR3 mRNA and protein expression and reduced telomerase activity ( $p < 0.05$ ); TERT and TR were not significantly reduced. The action of  $T_3$  at the growth plate may be partially mediated through the FGFR3 pathway.

**Conclusions:** The results suggest that FGFR3 inhibits chondrocyte proliferation by down-regulating TERT expression and reducing telomerase activity indicating an important role for telomerase in sustaining chondrocyte proliferative capacity during bone elongation.

**Keywords:** Chondrocytes, Growth-plate, Telomerase, Fibroblast growth factor receptor 3, Thyroid hormone, Sheep

## Background

Linear bone growth is a function of the proliferative capacity of the endochondral growth plate and the size of the hypertrophic cells. Regulators of chondrocyte proliferation greatly influence the rate and extent of long bone growth and the resulting mature skeletal size [1,2]. Fibroblast growth factor receptor 3 (FGFR3) is a critical regulator of growth plate chondrocyte function through its inhibition of proliferation [3,4]. Gain-of-function mutations in FGFR3 cause severe restriction of skeletal growth resulting in dwarfism in both mice and humans [5]. Loss-of-function mutations in sheep FGFR3 cause skeletal overgrowth through excessive proliferation of chondrocytes in the growth plate [6,7].

The inhibitory regulation by FGFR3 and its localized expression within the growth plate proliferative zone are unique among the family of four fibroblast growth factor receptors. The other FGFRs, 1, 2 and 4, promote proliferation and are primarily expressed in the perichondrium [8,9]. Evidence also suggests that FGFR1 may promote differentiation in the hypertrophic growth plate zone following exit from the proliferative zone [8,9].

Many hormones and growth factors beyond FGFR3 play a role in the function of the growth plate. Early findings from children pointed to a clear association between circulating thyroid hormone ( $T_3$ ) and skeletal size [10]. Thyroid hormone recruits resting zone growth plate chondrocytes to initiate proliferation but then inhibits further proliferation and induces hypertrophy to accelerate bone aging (reviewed in [11]); it also induces FGFR3 expression [12]. The inhibitory effects of  $T_3$  are

\* Correspondence: amoberbauer@ucdavis.edu  
Department of Animal Science, University of California, Davis, CA 95616, USA

balanced by growth factors that promote proliferation at the growth plate.

Chondrocytes within the growth plate undergo multiple rounds of proliferation to effect bone elongation [13]. Sustained proliferation of cells can lead to chromosomal degradation and DNA damage after consecutive replications unless telomere length is maintained [14]. Telomeres act as protective caps to the chromosomes and their length is maintained by telomerase, an enzyme consisting of a reverse transcriptase catalytic subunit (TERT) and a template RNA subunit (TR) moiety [15,16]. Several studies using human *in vitro* models have also demonstrated a growth-promoting role of telomerase and TERT that is independent of telomere-length maintenance [17-19], however this remains controversial [20]. Transfection experiments have shown that up-regulation of telomerase activity enhances proliferation and immortalizes cells whereas down-regulation of telomerase eventually leads to a halt in proliferation following critical telomere erosion [14,21,22].

Growth plate chondrocytes exhibit reduced proliferative capacity and cellular senescence as animals advance through puberty [23]. Although the mechanism controlling this gradual cessation of proliferation in growth plate chondrocytes is not well understood, human chondrocyte proliferation rates correlate with telomerase levels and both decline with advancing age [24]. A gain-of-function FGFR3 mutation in humans is correlated with reduced growth plate proliferation, shorter telomeres, reduced telomerase activity, and down-regulated TERT suggesting that FGFR3 may directly inhibit telomerase [24]. To determine if FGFR3 down-regulates telomerase activity, we hypothesized that reducing FGFR3 expression levels through siRNA would enhance chondrocyte proliferation, TERT mRNA expression, and telomerase activity whereas induction of FGFR3 via the addition of T<sub>3</sub> would have the opposite effect demonstrating coordination between inhibition of proliferation within the growth plate and conversion to the hypertrophic phenotype.

## Methods

### Cell culture

Costochondral growth plates were grossly excised from two commercial-bred male lambs at one week of age. The University of California, Davis Institutional Animal Use and Care Committee approved the experimental protocols for this study. For each trial, all dissected growth plates were digested to release growth plate chondrocytes as previously described [25] and pooled. Freed chondrocytes were layered onto a discontinuous isotonic gradient as described previously with the 1.0578 g/mL density fraction used as the source of the primary proliferative zone cells [26-28] and plated at

200,000 cells/well in 2 mL of Dulbecco's modified Eagle's medium (DMEM)/F12 (Gibco BRL, Grand Island, NY, USA) containing 5% fetal bovine serum (FBS) (Gibco), penicillin (100 U/mL) and streptomycin (100 mg/mL) (JRH Biosciences, Lenexa, KS) in 6 well tissue-culture plates. In all cultures chondrocytes were 98% viable, determined by trypan blue exclusion, at time of plating. After 1 day, the medium was replaced and cells were incubated for another day in complete media. Mitotic doubling time of chondrocytes was approximately 1.5 days. Primary growth plate chondrocytes under similar *in vitro* culture methods maintain their chondrocyte morphology and are resistant to dedifferentiation through 14 passages [25,29]. In the present experiment, the cells were cultured for approximately one week with fewer than five mitotic doublings and the chondrocyte phenotype was confirmed by using ovine specific PCR primers [30]. Isolated cells expressed type II collagen mRNA throughout the culture period. The entire primary chondrocyte isolation procedure and treatments were repeated at a later time in a replicate of the trial. For each trial, the experimental unit was culture well with each treatment replicated in three wells. The data reported represent the results of the treatment replicates for the two trials. Notably, a trial effect was not discernible statistically.

### siRNA transfection

Proliferative zone chondrocytes were transfected 2 days post plating with double stranded RNA (dsRNA) oligos to mediate post-transcriptional degradation of FGFR3 and FGFR2 mRNA. The siRNA oligos (Table 1) were designed from published mRNA sequences (GenBank: AY737276; AJ320477) using the Stealth RNAi designer (Invitrogen, Carlsbad CA). Proliferative zone chondrocytes were lipofectamine transfected as per kit instructions (BLOCK-IT transfection kit; Invitrogen) at a final concentration of 100 nM dsRNA per well for each oligo sequence transfected. Untransfected chondrocyte cultures were also used as a 'baseline' control to account for any direct effects of lipofectamine on treated chondrocytes. A GFP reporter plasmid (fluorescein-labeled, Invitrogen, Carlsbad, CA), cultured in parallel to the treated chondrocytes, was used as a transfection efficiency control. After a 24-hour incubation period post-transfection, transfection efficiency was measured by counting the proportion of strongly fluorescing cells containing the GFP reporter plasmid. The proliferative zone chondrocyte transfection efficiency for the GFP reporter plasmid was approximately 68%. A scrambled dsRNA (ScR) was transfected and used as control cultures for determining the effect of the targeted FGFR3 siRNA knockdown. Growth plate proliferative zone chondrocytes also express minimally FGFR2, a receptor known to promote

**Table 1 Oligo sequences and accession numbers**

	Sequence (5' to 3')	Strand	Accession
<b>siRNA oligos</b>			
FGFR3	CAGGUGUCCUUGGAGUCCAGUUCAU	Sense	AY737276
	AUGAACUGGACUCCAAGGACACCUG	Anti-sense	
FGFR2	GGGAUAUACGUGCUUGGCGGUAA	Sense	AJ320477
	UUACCCGCCAAGCACGUAAUUC	Anti-sense	
Scrambled control (ScR)	CAGUGCCUUGGACUACUGUUGCAU	Sense	Invitrogen
	AUGCAACAGUAGUCCAAGGCACUG	Anti-sense	
<b>Real-Time PCR primers</b>			
FGFR3	CGCAGGACACCAGGTCTTTG	Forward	NM 174318.3
	cggcTACTCCTTCGACACCTGCG	Reverse	
TERT	CGTCTCTCTGCTCTGCTC	Forward	NM 001046242.1
	cggacGATGGTTCCACGAGTGTC	Reverse	
TR	GCAGACTGGATGGTGGATGG	Forward	NR 001576.1
	cggtaCGCTGTCTTTGGTTACG	Reverse	
Kanamycin resistance - Exogenous Standard	AAGCCCACTGCAAGCTACCTG	Forward	Invitrogen PCRIII vector based amplicon
	CGTTTTGGCTATCTGGACAAGGGAAA	Reverse	

chondrocyte replication [31]. To eliminate confounding effects of FGFR2 on proliferation all experimental chondrocyte cultures regardless of additional treatments, including the ScR control, were subjected to FGFR2 siRNA knockdown (Table 2).

#### Hormonal treatments

Hormonal treatments to enhance FGFR3 expression and activation were given 1 day post siRNA transfection: the lipofectamine-dsRNA transfection solution was removed and replaced with 2 mL/well of complete media containing the appropriate hormonal treatment. Recombinant human FGF18 (30 pM, Peprotech, Rocky Hill NJ), an FGFR3 ligand, was added to all cultures to activate the receptor [32]. To enhance FGFR3 expression 1 μM tri-iodothyronine (T<sub>3</sub>) (SIGMA, St. Louis, MO) was added to mediate transcriptional up regulation of FGFR3

**Table 2 Treatments applied to isolated growth plate proliferative chondrocytes: double stranded RNA (dsRNA) oligos to mediate post-transcriptional degradation of FGFR3 (siRNA FGFR3) and FGFR2 mRNA (siRNA FGFR2), scrambled dsRNA as control, 30 pM recombinant human FGF18, or 1 μM tri-iodothyronine (T3)**

Treatment	ScR	siRNA	T3
siRNA FGFR3	-	+	-
scrambled dsRNA	+	-	-
thyroid hormone	-	-	+
siRNA FGFR2	+	+	+
FGF18	+	+	+

mRNA [12]. Chondrocytes from culture wells were harvested at 3, 5, and 7 days post siRNA transfection by digestion with 2.5% trypsin (without phenol red, calcium, or magnesium) (1 ml/well) for 15 min at 5% CO<sub>2</sub> and 37°C followed by 3 mg/mL collagenase type II in DMEM/F12/5% FBS (2 mL/well) for 45 min. Following digestion, cell aggregates were gently triturated with a glass pipette, scraped, and collected. The cells were centrifuged at 150 × g to pellet for supernatant removal. Cells were washed in 1X PBS and centrifuged again and the cell pellet snap frozen in liquid nitrogen and stored at -80°C until DNA, RNA, or protein isolation.

#### Isolation and quantification of DNA, RNA, and protein

Thawed cell pellets were mechanically lysed in 50 μl 1X PBS by trituration through a small bore pipet tip. The lysate was homogenized using a Qiashredder spin-column according to manufacturer recommendations (Qiagen, Germantown, MD). Approximately 10% of the cell lysate volume was removed, diluted 1:10 in CHAPS lysis buffer, snap frozen in liquid nitrogen, and stored at -80°C. DNA, RNA, and protein were isolated from the remaining aliquot of the cell lysate (All Prep™ kit, Qiagen, Germantown, MD). A Qubit fluorometer based Quant-it assay (Invitrogen, Molecular Probes Inc., Eugene, OR) was used to determine the DNA, RNA, and protein concentration of each well sample; all wells were replicated in triplicate under each treatment. Chondrocyte proliferation was determined by quantifying DNA concentration of chondrocyte cultures at 3, 5, and 7 days post siRNA transfection [33].

### Two-step real-time quantitative PCR (qPCR)

Culture mRNAs were transcribed to cDNA with the iScript cDNA synthesis kit (Bio-Rad, Hercules CA) containing oligo d(t) and random-hexamer primers in a 20  $\mu$ l reaction (4  $\mu$ l 5X iScript reaction mix, 1  $\mu$ l iScript reverse transcriptase, remaining 15  $\mu$ l water and 500 ng total RNA) as per the manufacturer's recommended protocol. The resulting reaction volume was diluted 1:5 with DEPC water and stored at  $-20^{\circ}\text{C}$ .

Fluorescent-reporter specific primers for real-time qPCR were designed using the Invitrogen online D-Lux designer (Invitrogen, Carlsbad CA) and published mRNA sequences for FGFR3, TR and TERT (Table 1, GenBank: NM\_174318.3, NR\_001576.1, and NM\_001046242.1, respectively). All real-time qPCR reactions were run in 96-well plates using UDG-Supermix (Invitrogen, Carlsbad CA). Each reaction contained 10  $\mu$ M of each primer (forward and reverse), and 5  $\mu$ l diluted cDNA, in a final volume of 50  $\mu$ l. Samples were amplified in an MJ Research Chromo 4 Detector (BioRad, Hercules CA) with one cycle of  $50^{\circ}\text{C}$  for 2 min and  $95^{\circ}\text{C}$  for 2 min, followed by 49 cycles of  $95^{\circ}\text{C}$  for 15 sec,  $60^{\circ}\text{C}$  for 30 sec with a ramp rate of  $2^{\circ}\text{C}$  per sec. Fluorescence was collected during each plate read immediately following the annealing period at  $60^{\circ}\text{C}$ .

The C(t) values were quantified in femtograms using a standard curve equation defined by five serially diluted concentrations of an exogenous cDNA [19]. In this case, the exogenous cDNA standard encoded a kanamycin resistance gene [34] originally constructed as a 1000 bp RNA portion of an Invitrogen pCRII vector. The kanamycin resistance standard RNA was reverse transcribed into cDNA in tandem with the chondrocyte RNA samples it quantified. The C(t) threshold and baseline definitions were held constant for all replicates of a gene signal within each experiment.

### Telomerase activity detection

A TRAPeze Telomerase Detection Kit (Chemicon (Millipore), Temecula, CA) was used to determine telomerase activity in the thawed chondrocyte lysate samples, using real-time quantitative PCR-based amplification of telomeric repeats in an MJ Research Chromo 4 Detector (BioRad, Hercules CA) following the manufacturer's recommended program. The C(t) values were determined manually by defining the beginning of the linear phase in the log-based fluorescence and the best fit of the standard curve. The C(t) values were quantified in zmoles using a standard curve equation defined by five serially diluted concentrations of a telomerase substrate included in the kit as a quantitation control.

### Western blotting

Equal concentrations of cellular protein isolated as detailed above were suspended in a Laemmli-related

sample buffer (ALO, All Prep™ kit, Qiagen, Germantown, MD), incubated at  $90^{\circ}\text{C}$  for 4 min, separated on a 10% SDS-PAGE gel, and transferred to a PVDF membrane (Amersham, GE Healthcare, Piscataway, NJ) by electroblotting (30 V, 0.12 mA/cm<sup>2</sup> overnight). Following transfer, the PVDF membrane was blocked 1 hour in 5% non-fat dry milk/0.1% Tween in TBS, washed for 10 min in 0.1% Tween-20 in TBS, and incubated with 5% BSA and 0.1% Tween-20 in TBS containing either the FGFR3 (0.4  $\mu$ g/mL, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, #sc-31162) or GAPDH (0.1  $\mu$ g/mL, Millipore, Billerica, MA #MAB374) primary antibodies for 2.5 hours at  $4^{\circ}\text{C}$ . After primary antibody hybridization, the membranes were washed 3 times with 0.1% Tween-20 in TBS and incubated with a secondary antibody. Immunoblotting was done with horseradish peroxidase-conjugated anti-rabbit or anti-mouse secondary antibodies (Jackson ImmunoResearch, West Grove, PA, 0.04  $\mu$ g/mL, #711-035-152, #715-035-151) and ECL detection reagents and film according to manufacturer's instructions (Amersham, GE Healthcare, Piscataway, NJ). Immunoblots were digitally captured (Alpha Innotech® ChemImager™ model 4400) and protein levels were quantified (Alpha Innotech® Spotdenso software for densitometric scanning of bands); GAPDH intensities were used as a loading control and densitometry values adjusted prior to comparing for treatment effects.

### Statistical analyses

For each trial, each treatment was performed in triplicate. The entire trial was replicated using a second preparation of primary chondrocytes. Chondrocyte cell culture data were analyzed with day, trial, siRNA transfection, and T<sub>3</sub> as the main effects using least squares analysis of variance (ANOVA) to determine statistical significance (PROC GLM, Procedure General Linear Model, SAS version 9.1; SAS Institute Inc., Cary, NC). General linear model analysis of DNA concentration, telomerase activity, mRNA and protein expression levels included Tukey pairwise comparison tests of treatment groups. Statistical significance was defined as  $P < 0.05$  and all data are expressed as the mean  $\pm$  standard error of the mean.

## Results

### FGFR3 siRNA

Untransfected baseline control chondrocytes were not significantly different from ScR control treated chondrocytes, or chondrocytes treated with vehicle controls, for the DNA, mRNA, or protein quantity evaluated at all post transfection days sampled ( $p > 0.2$ , data not shown). At 3 days post transfection, cells treated with FGFR3 siRNA had a 57% reduction in FGFR3 mRNA. There was a 55% reduction in FGFR3 protein levels relative to


ScR control treated cells (and untransfected controls):  $0.61 \pm 0.13$  and  $1.36 \pm 0.34$  arbitrary densitometric units, respectively ( $p < 0.05$ , Figure 1). The reduction in FGFR3 mRNA persisted through 7 days post transfection.

In response to  $T_3$  treatment, FGFR3 mRNA was increased ( $p < 0.05$ , Figure 1). At 3 and 7 days post transfection,  $T_3$  treated cells had increased FGFR3 mRNA levels relative to cells without  $T_3$  exposure of 79.1%, and 61.2%, respectively, FGFR3 protein levels followed the increase in mRNA:  $3.05 \pm 0.84$  and  $1.36 \pm 0.34$  arbitrary densitometric units for  $T_3$  treated cells relative to ScR control treated cells, respectively ( $p < 0.05$ , Figure 1).

### Chondrocyte proliferation

To examine the effects of FGFR3 on chondrocyte proliferation in FGFR3 siRNA treated cells, DNA concentration

was used as a measurement of cell number. In preliminary experiments we established a direct correlation between cell counts and DNA concentration. Quantifying DNA concentration has also been shown to be a robust indicator of cell number [35]. Seven days post FGFR3 siRNA transfection has been shown to be sufficient time for determining the effects of FGFR3 siRNA on cell proliferation [36]. At 3 and 5 days post siRNA transfection, there was no significant difference in DNA concentration between ScR and FGFR3 siRNA, treated chondrocytes ( $p > 0.2$ , Table 3). At day 5,  $T_3$  treated chondrocytes had reduced DNA concentration. However, at 7 days post siRNA transfection chondrocytes treated with FGFR3 siRNA had significantly greater DNA concentration ( $p < 0.05$ ), hence cell number, relative to the  $T_3$  and ScR control treatments with the latter two treatments not differing from one another ( $p > 0.2$ ).




### Telomerase expression and activity

Chondrocytes treated with FGFR3 siRNA had elevated telomerase activity compared to that detected for control chondrocytes whereas chondrocytes treated with  $T_3$  showed a reduction in telomerase activity relative to the ScR control at 3 days ( $p < 0.05$ ). Specifically, FGFR3 siRNA chondrocytes had ~80% more telomerase activity than ScR chondrocytes, which in turn had more than 3-fold greater telomerase activity than chondrocytes treated with  $T_3$  at 3 days post siRNA transfection ( $p < 0.05$ , Figure 2). The difference was not maintained at 7 days. Expression of telomerase subcomponent TERT was significantly increased in response to siRNA at 3 days post exposure ( $1.83 \pm 0.27$  and  $0.85 \pm 0.07$  femtogram for siRNA and ScR, respectively;  $p < 0.05$ ). In contrast, exposure to  $T_3$  did not significantly alter TERT ( $0.85 \pm 0.07$  and  $0.56 \pm 0.24$  fg for ScR and  $T_3$ , respectively;  $p = 0.2$ ). Real-time qPCR analysis of TR mRNA levels showed no difference for the siRNA, ScR control, and  $T_3$  treatments:  $244.57 \pm 49.40$ ,  $262.90 \pm 49.40$ ,  $250.20 \pm 49.40$  femtogram, respectively ( $p = 0.8$ ), on day 3.

**Table 3 Chondrocyte proliferation as indicated by DNA concentration ( $\mu\text{g/mL}$ ) in response to siRNA transfected, scrambled control (ScR) transfected, or thyroid hormone ( $T_3$ ) treatment over time**

	Treatment		
	ScR	siRNA	$T_3$
Day 3	$13.8 \pm 1.9$	$17.0 \pm 1.5$	$15.7 \pm 2.4$
Day 5	$28.7 \pm 0.6$	$26.3 \pm 1.0$	$15.8 \pm 1.0^*$
Day 7	$34.3 \pm 1.8$	$52.9 \pm 2.9^*$	$34.2 \pm 0.6$

\* asterisk denotes difference ( $p < 0.05$ ) between treatment means for a given day; data are presented as mean  $\pm$  SEM.



**Figure 2** FGFR3 effects on telomerase activity. Proliferative zone chondrocytes treated with siRNA to reduce FGFR3 and  $T_3$  to increase FGFR3 were compared to ScR controls. Data are presented as means  $\pm$  SEM. An asterisk (\*) designates that means for a given day differed from ScR control at  $p < 0.05$ . Untransfected chondrocyte cultures were not significantly different from ScR controls (data not shown).

## Discussion

The purpose of the present study was to experimentally evaluate effects of altered FGFR3 expression on proliferation and telomerase activity in sheep growth plate chondrocytes. Wild type growth plate chondrocytes were used in the present study instead of chondrocytes from FGFR3 loss-of-function mutants to more tightly model normal physiological conditions. The knockdown level of approximately 55% achieved in this study has been previously characterized as sufficient for downstream effects of other proliferation inhibitor genes such as p53 [37]. By reducing FGFR3 expression through siRNA transfection, chondrocytes exhibited enhanced proliferation when released from FGFR3 mediated growth inhibition, a finding similar to that seen in human adenocarcinoma cells [36].

To enhance FGFR3 expression, chondrocytes were exposed to  $T_3$  at doses comparable to published studies [12,38-41]. Chondrocytes treated with  $T_3$  had double the FGFR3 mRNA levels relative to that detected in controls. Surprisingly, there was no significant sustained effect of  $T_3$  on cell proliferation in response to the increased FGFR3. Though reduced chondrocyte proliferation was expected upon exposure to  $T_3$ , studies have reported that monolayer chondrocyte cultures respond to  $T_3$  treatment with increased maturation rather than altered proliferation [41]. The  $T_3$  effect on chondrocyte maturation is suggested to be mediated by FGFR3 [12]. In humans with genetically over-expressed FGFR3, chondrocyte maturation was correlated with reduced telomerase activity [24]. For the present study,  $T_3$  was employed to increase FGFR3 expression within proliferative zone chondrocytes and resulted in a down regulation of telomerase activity.

With differentiation of growth plate chondrocytes, telomerase activity would be expected to decline [24]. The target for telomerase down-regulation in mammals is the reverse transcriptase catalytic subunit (TERT) [15,42]. The proliferative chondrocytes of the present study showed ubiquitous TR expression and low levels of TERT mRNA expression in chondrocytes with normal FGFR3 expression. Reducing FGFR3 increased proliferation and telomerase activity suggesting that reducing levels of FGFR3 can increase the activity of telomerase sufficiently to support the replication of the chondrocytes. Ectopic expression of TERT has been shown to enhance proliferation and immortalize cells in culture [17-19]. Elevated TERT expression observed with reduced FGFR3, and lower telomerase levels when chondrocytes had elevated FGFR3 in response to  $T_3$  suggest that induction of FGFR3 mediates  $T_3$  action as a negative regulator of telomerase. It must be noted however that other growth factors are influenced by elevated  $T_3$  [10] and the telomerase effects observed may also reflect the contributions of other factors.

Most somatic cells diminish telomerase activity after prenatal development and begin a process of gradual telomere erosion with each replication cycle known as the "mitotic clock" [15,16]. In contrast, tissues requiring rapid and continual proliferation maintain telomerase activity to conserve the integrity of chromosomal structure through sustained replication events [15,16]. Growth plate chondrocytes have active telomerase [43], yet exhibit senescence at an earlier age relative to most somatic cells [23] undergoing only 3 to 5 rounds of mitosis before differentiation and eventual apoptosis [13]. Early senescence and few replicative cycles does not support the need to maintain chromosomal ends and sustained telomerase activity. This would imply that telomere maintenance should not be required in proliferative zone chondrocytes. Yet, telomerase activity does increase with differentiation and progression of chondrocytes through the resting, proliferative, and hypertrophic zones [24]. Taken together, that would suggest an alternate role for telomerase within the growth plate that may involve cellular proliferation [18] as well as promoting differentiation [24,44].

Telomerase has been shown to increase proliferation and delay apoptosis in cells [18], whereas FGFR3 promotes apoptosis and cessation of proliferation in the growth plate [1,45]. In vivo, the presence of a single functional FGFR3 copy results in enhanced skeletal growth and delayed maturation [6,7]. Reduced FGFR3 expression may enhance telomerase activity, increase growth plate chondrocyte proliferation and delay apoptosis, thereby enabling greater endochondral bone growth resulting in a larger mature skeletal size. The opposite would also be true; thus, pharmaceutical

interventions used in the down-regulation of telomerase to control cancer [46] may impact growth plate function if given to juveniles. The role of telomerase in both supporting proliferation and then in the subsequent cessation of proliferation are areas that needs further exploration and such studies may shed light on the mechanisms regulating closure of the growth plate.

## Conclusions

The present study demonstrated that reduced FGFR3 expression confers increased proliferative capacity on growth plate chondrocytes through enhanced TERT levels in vitro and suggests a likely translation to enhanced overall bone length in vivo. Collectively the data suggest that normal FGFR3 inhibits cell proliferation by reducing telomerase through down regulating TERT expression and telomerase activity, indicating an important role for telomerase in sustaining chondrocyte proliferative capacity and rate during bone elongation. Further, these findings suggest that the action of T<sub>3</sub> on growth plate chondrocyte function may be partially mediated by FGFR3 and its effects on telomerase. Although regulation of chondrocyte activity as the growth plate approaches closure is incompletely understood, results of the present study suggest that FGFR3 may play a pivotal role.

## Abbreviations

BSA: Bovine serum albumin; cDNA: Copy DNA; CHAPS: 3[[3-Cholamidopropyl) dimethylammonio]-propanesulfonic acid; DNA: Deoxyribonucleic acid; DEPC: Diethylpyrocarbonate; DMEM: Dulbecco's modified Eagle's medium; ECL: Enhanced chemiluminescence; FBS: Fetal bovine serum; FGF: Fibroblast growth factor; FGFR: Fibroblast growth factor receptor; GAPDH: Glyceraldehyde 3-phosphate dehydrogenase; mRNA: Messenger RNA; PBS: Phosphate buffered saline; PCR: Polymerase chain reaction; PVDF: Polyvinylidene fluoride; qPCR: Quantitative PCR; RNA: Ribonucleic acid; ScR: Scrambled DNA transfection control; siRNA: Small interfering RNA; TBS: Tris buffered saline; T<sub>3</sub>: Tri-iodothyronine; TERT: Reverse transcriptase catalytic subunit of telomerase; TR: Template RNA subunit of telomerase; Zmoles: Zepto moles ( $\times 10^{21}$ ).

## Competing interests

The authors declare that they have no competing interests.

## Authors' contributions

LBS participated in study design, carried out the experiment, and drafted the manuscript; JMB provided input in study design, analysis, and drafting the manuscript; AMO participated in study design, analysis, study coordination, and drafting the manuscript. All authors have read and approved the final manuscript.

## Acknowledgements

This work was supported by W.K. Kellogg Endowment, and the authors gratefully acknowledge the infrastructure support of the Department of Animal Science, College of Agricultural and Environmental Sciences, and the California Agricultural Experiment Station of the University of California-Davis (CA-D\*-ASC-5256-AH). LBS received financial assistance from Scholarships funded by the Ford Family Foundation and the endowment of G. Kirk Swingle. The authors thank Dr. Mary Delany and Dr. Clare Yellowley for assistance with materials and editorial reviewing of the manuscript.

Received: 13 August 2012 Accepted: 3 December 2012  
Published: 7 December 2012

## References

1. Matsushita T, Wilcox WR, Chan YY, Kawanami A, Bükülmez H, Balmes G, Krejci P, Mekikian PB, Otani K, Yamaura I, et al: **FGFR3 promotes synchondrosis closure and fusion of ossification centers through the MAPK pathway.** *Hum Mol Genet* 2009, **18**:227–240.
2. Oberbauer AM, Currie WB, Krook L, Thonney ML: **Endocrine and histologic correlates of the dynamics of the metacarpal growth plate in growing rams.** *J Anim Sci* 1989, **67**:3124–3135.
3. Colvin JS, Bohne BA, Harding GW, McEwen DG, Ornitz DM: **Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3.** *Nat Genet* 1996, **12**:390–397.
4. Deng C, Wynshaw-Boris A, Zhou F, Kuo A, Leder P: **Fibroblast growth factor receptor 3 is a negative regulator of bone growth.** *Cell* 1996, **84**:911–921.
5. Shiang R, Thompson LM, Zhu YZ, Church DM, Fielder TJ, Bocian M, Winokur ST, Wasmuth JJ: **Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia.** *Cell* 1994, **78**:335–342.
6. Beever JE, Smit MA, Meyers SN, Hadfield TS, Bottema C, Albretsen J, Cockett NE: **A single-base change in the tyrosine kinase II domain of ovine FGFR3 causes hereditary chondrodysplasia in sheep.** *Anim Genet* 2006, **37**:66–71.
7. Smith LB, Dally MR, Sainz RD, Rodrigue KL, Oberbauer AM: **Enhanced skeletal growth of sheep heterozygous for an inactivated fibroblast growth factor receptor 3.** *J Anim Sci* 2006, **84**:2942–2949.
8. Delezoide AL, Benoist-Lasselin C, Legeai-Mallet L, Le Merrer M, Munnich A, Vekemans M, Bonaventure J: **Spatio-temporal expression of FGFR 1, 2 and 3 genes during human embryo-fetal ossification.** *Mech Dev* 1998, **77**:19–30.
9. Wang Q, Green RP, Zhao G, Ornitz DM: **Differential regulation of endochondral bone growth and joint development by FGFR1 and FGFR3 tyrosine kinase domains.** *Development* 2001, **128**:3867–3876.
10. Wojcicka A, Bassett J, Williams GR: **Mechanisms of action of thyroid hormones in the skeleton.** *Biochim Biophys Acta, Gen Subj* 2012, doi:10.1016/j.bbagen.2012.05.005.
11. Mackie EJ, Tatarczuch L, Mirams M: **The skeleton: a multi-functional complex organ. The growth plate chondrocyte and endochondral ossification.** *J Endocrinol* 2011, **211**:109–121.
12. Barnard JC, Williams AJ, Rabier B, Chassande O, Samarut J, Cheng S, Bassett JHD, Williams GR: **Thyroid hormones regulate fibroblast growth factor receptor signaling during chondrogenesis.** *Endocrinology* 2005, **146**:5568–5580.
13. Farnum C, Wilsman N: **Determination of proliferative characteristics of growth plate chondrocytes by labeling with bromodeoxyuridine.** *Calcif Tissue Int* 1993, **52**:110–119.
14. Blackburn EH: **Structure and function of telomeres.** *Nature* 1991, **350**:569–573.
15. Davis T, Kipling D: **Telomeres and telomerase biology in vertebrates: progress towards a non-human model for replicative senescence and ageing.** *Biogerontology* 2005, **6**:371–385.
16. O'Hare T, Delany M: **Telomerase gene expression in the chicken: telomerase RNA (TR) and reverse transcriptase (TERT) transcript profiles are tissue-specific and correlate with telomerase activity.** *Age* 2005, **27**:257–266.
17. Choi J, Southworth LK, Sarin KY, Venteicher AS, Ma W, Chang W, Cheung P, Jun S, Artandi MK, Shah N, et al: **TERT promotes epithelial proliferation through transcriptional control of a Myc- and Wnt-related developmental program.** *PLoS Genet* 2008, **4**:e10.
18. Gorbunova V, Seluanov A: **Telomerase as a growth-promoting factor.** *Cell Cycle* 2003, **2**:534–537.
19. Smith LL, Collier HA, Roberts JM: **Telomerase modulates expression of growth-controlling genes and enhances cell proliferation.** *Nat Cell Biol* 2003, **5**:474–479.
20. Vidal-Cardenas SL, Greider CW: **Comparing effects of mTR and mTERT deletion on gene expression and DNA damage response: a critical examination of telomere length maintenance-independent roles of telomerase.** *Nucleic Acids Res* 2010, **38**:60–71.
21. Katzenellenbogen RA, Vliet-Gregg P, Xu M, Galloway DA: **NFX1-123 increases hTERT expression and telomerase activity posttranscriptionally in human papillomavirus type 16 E6 keratinocytes.** *J Virol* 2009, **83**:6446–6456.

22. Kim H, Farris J, Christman SA, Kong B-W, Foster LK, O'Grady SM, Foster DN: Events in the immortalizing process of primary human mammary epithelial cells by the catalytic subunit of human telomerase. *Biochem J* 2002, **365**:765–772.
23. Schrier L, Ferns SP, Barnes KM, Emons JAM, Newman EI, Nilsson O, Baron J: Depletion of resting zone chondrocytes during growth plate senescence. *J Endocrinol* 2006, **189**:27–36.
24. Morita M, Nakanishi K, Kawai T, Fujikawa K: Telomere length, telomerase activity, and expression of human telomerase reverse transcriptase mRNA in growth plate of epiphyseal articular cartilage in femoral head during normal human development and in thanatophoric dysplasia. *Hum Pathol* 2004, **35**:403–411.
25. Oberbauer AM, Peng R: Fractionation of growth plate chondrocytes: differential expression of IGF-I and growth hormone and IGF-I receptor mRNA in purified populations. *Connect Tissue Res* 1995, **31**:179–187.
26. Evans KD, Oberbauer AM: Spatiotemporal localization of VEGF-A isoforms in the mouse postnatal growth plate. *Anat Rec* 2008, **291**:6–13.
27. Olney RC, Mougey EB: Expression of the components of the insulin-like growth factor axis across the growth-plate. *Mol Cell Endocrinol* 1999, **156**:63–71.
28. Ellsworth JL, Berry J, Bukowski T, Claus J, Feldhaus A, Holderman S, Holdren MS, Lum KD, Moore EE, Raymond F, et al: Fibroblast growth factor-18 is a trophic factor for mature chondrocytes and their progenitors. *Osteoarthr Cartil* 2002, **10**:308–320.
29. Oberbauer AM, Peng R: Growth hormone and IGF-I stimulate cell function in distinct zones of the rat epiphyseal growth plate. *Connect Tissue Res* 1995, **31**:189–195.
30. Dorotka R, Windberger U, Macfelda K, Bindreiter U, Toma C, Nehrer S: Repair of articular cartilage defects treated by microfracture and a three-dimensional collagen matrix. *Biomaterials* 2005, **26**:3617–3629.
31. Lazarus JE, Hegde A, Andrade AC, Nilsson O, Baron J: Fibroblast growth factor expression in the postnatal growth plate. *Bone* 2007, **40**:577–586.
32. Ellsworth J, Berry J, Bukowski T, Claus J, Feldhaus A, Holderman S, Holdren M, Lum K, Moore E, Raymond F: Fibroblast growth factor-18 is a trophic factor for mature chondrocytes and their progenitors. *Osteoarthr Cartil* 2002, **10**:308–320.
33. Otto WR: Fluorimetric DNA assay of cell number. *Method Mol Biol-Clifton Then Totowa* 2005, **289**:251–262.
34. Caelers A, Berishvili G, Meli ML, Eppler E, Reinecke M: Establishment of a real-time RT-PCR for the determination of absolute amounts of IGF-I and IGF-II gene expression in liver and extrahepatic sites of the tilapia. *Gen Comp Endocrinol* 2004, **137**:196–204.
35. Otto WR: Fluorimetric DNA assay of cell number. *Methods Mol Biol* 2005, **289**:251–262.
36. Estes NR, Thottassery JV, Kern FG: siRNA mediated knockdown of fibroblast growth factor receptors 1 or 3 inhibits FGF-induced anchorage-independent clonogenicity but does not affect MAPK activation. *Oncol Rep* 2006, **15**:1407–1416.
37. Lo HW, Stephenson L, Cao X, Milas M, Pollock R, Ali-Osman F: Identification and functional characterization of the human glutathione S-transferase P1 gene as a novel transcriptional target of the p53 tumor suppressor gene. *Mol Cancer Res* 2008, **6**:843–850.
38. Ohlsson C, Nilsson A, Lindahl A: Effects of tri-iodothyronine and insulin-like growth factor-I (IGF-I) on alkaline phosphatase activity, [3H] thymidine incorporation and IGF-I receptor mRNA in cultured rat epiphyseal chondrocytes. *J Endocrinol* 1992, **135**:115–123.
39. Ballock RT, Zhou X, Mink LM, Chen DH, Mita BC, Stewart MC: Expression of cyclin-dependent kinase inhibitors in epiphyseal chondrocytes induced to terminally differentiate with thyroid hormone. *Endocrinology* 2000, **141**:4552–4557.
40. Stevens DA, Hasserjian RP, Robson H, Siebler T, Shalet SM, Williams GR: Thyroid hormones regulate hypertrophic chondrocyte differentiation and expression of parathyroid hormone-related peptide and its receptor during endochondral bone formation. *J Bone Miner Res* 2000, **15**:2431–2442.
41. Robson H, Siebler T, Stevens DA, Shalet SM, Williams GR: Thyroid hormone acts directly on growth plate chondrocytes to promote hypertrophic differentiation and inhibit clonal expansion and cell proliferation. *Endocrinology* 2000, **141**:3887–3897.
42. Cong Y-S, Wright WE, Shay JW: Human telomerase and its regulation. *Microbiol Mol Biol Rev* 2002, **66**:407–425.
43. Nwosu BU, Nilsson O, Mitchum RD Jr, Coco M, Barnes KM, Baron J: Lack of telomere shortening with age in mouse resting zone chondrocytes. *Horm Res Paediatr* 2005, **63**:125–128.
44. Serakinci N, Graakjaer J, Kolvraa S: Telomere stability and telomerase in mesenchymal stem cells. *Biochimie* 2008, **90**:33–40.
45. Legeai-Mallet L, Benoist-Lassel C, Delezoide A-L, Munnich A, Bonaventure J: Fibroblast growth factor receptor 3 mutations promote apoptosis but do not alter chondrocyte proliferation in thanatophoric dysplasia. *J Biol Chem* 1998, **273**:13007–13014.
46. Tokcaer-Keskin Z, Dikmen ZG, Ayaloglu-Butun F, Gultekin S, Gryaznov SM, Akcali KC: The effect of telomerase template antagonist GRN163L on bone-marrow-derived Rat mesenchymal stem cells is reversible and associated with altered expression of cyclin d1, cdk4 and cdk6. *Stem Cell Rev* 2010, Online First epub.

doi:10.1186/2049-1891-3-39

Cite this article as: Smith et al.: Fibroblast growth factor receptor 3 effects on proliferation and telomerase activity in sheep growth plate chondrocytes. *Journal of Animal Science and Biotechnology* 2012 **3**:39.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
www.biomedcentral.com/submit

